Saudi Pharmaceutical Industries and Medical Appliances Valuation
Is 2070 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 2070 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 2070 (SAR28.7) is trading below our estimate of fair value (SAR29.62)
Significantly Below Fair Value: 2070 is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2070?
Other financial metrics that can be useful for relative valuation.
What is 2070's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ر.س3.44b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 2.8x |
Enterprise Value/EBITDA | 29.1x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 2070's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 5.1x | ||
4016 Middle East Pharmaceutical Industries | 7x | 12.5% | ر.س2.5b |
4015 Jamjoom Pharmaceuticals Factory | 8.3x | 12.3% | ر.س9.9b |
300119 Tianjin Ringpu Bio-TechnologyLtd | 2.8x | 16.0% | CN¥6.6b |
MEGA Mega Lifesciences | 2.1x | 4.6% | ฿32.7b |
2070 Saudi Pharmaceutical Industries and Medical Appliances | 2.2x | 9.6% | ر.س3.4b |
Price-To-Sales vs Peers: 2070 is good value based on its Price-To-Sales Ratio (2.2x) compared to the peer average (5.1x).
Price to Earnings Ratio vs Industry
How does 2070's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?
Price-To-Sales vs Industry: 2070 is good value based on its Price-To-Sales Ratio (2.2x) compared to the Asian Pharmaceuticals industry average (2.4x).
Price to Sales Ratio vs Fair Ratio
What is 2070's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 2.2x |
Fair PS Ratio | 3.3x |
Price-To-Sales vs Fair Ratio: 2070 is good value based on its Price-To-Sales Ratio (2.2x) compared to the estimated Fair Price-To-Sales Ratio (3.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | ر.س28.70 | ر.س33.33 +16.1% | 8.3% | ر.س37.00 | ر.س30.30 | n/a | 4 |
Jun ’25 | ر.س31.20 | ر.س36.83 +18.0% | 14.4% | ر.س45.00 | ر.س30.30 | n/a | 4 |
May ’25 | ر.س37.55 | ر.س36.64 -2.4% | 13.0% | ر.س45.00 | ر.س30.30 | n/a | 5 |
Apr ’25 | ر.س34.40 | ر.س34.88 +1.4% | 16.6% | ر.س45.00 | ر.س27.50 | n/a | 5 |
Mar ’25 | ر.س38.15 | ر.س34.88 -8.6% | 16.6% | ر.س45.00 | ر.س27.50 | n/a | 5 |
Feb ’25 | ر.س34.15 | ر.س34.88 +2.1% | 16.6% | ر.س45.00 | ر.س27.50 | n/a | 5 |
Jan ’25 | ر.س38.05 | ر.س34.88 -8.3% | 16.6% | ر.س45.00 | ر.س27.50 | n/a | 5 |
Dec ’24 | ر.س36.05 | ر.س34.88 -3.2% | 16.6% | ر.س45.00 | ر.س27.50 | n/a | 5 |
Nov ’24 | ر.س29.95 | ر.س36.28 +21.1% | 15.9% | ر.س45.00 | ر.س27.50 | n/a | 5 |
Oct ’24 | ر.س35.00 | ر.س42.83 +22.4% | 21.4% | ر.س55.50 | ر.س34.00 | n/a | 3 |
Sep ’24 | ر.س37.60 | ر.س42.83 +13.9% | 21.4% | ر.س55.50 | ر.س34.00 | n/a | 3 |
Aug ’24 | ر.س39.70 | ر.س37.83 -4.7% | 34.7% | ر.س55.50 | ر.س24.00 | n/a | 3 |
Jul ’24 | n/a | ر.س26.00 0% | 7.7% | ر.س28.00 | ر.س24.00 | n/a | 2 |
Jun ’24 | ر.س38.75 | ر.س26.00 -32.9% | 7.7% | ر.س28.00 | ر.س24.00 | ر.س31.20 | 2 |
May ’24 | ر.س25.20 | ر.س26.00 +3.2% | 7.7% | ر.س28.00 | ر.س24.00 | ر.س37.55 | 2 |
Apr ’24 | ر.س23.74 | ر.س26.00 +9.5% | 7.7% | ر.س28.00 | ر.س24.00 | ر.س34.40 | 2 |
Mar ’24 | ر.س22.06 | ر.س26.00 +17.9% | 7.7% | ر.س28.00 | ر.س24.00 | ر.س38.15 | 2 |
Feb ’24 | ر.س23.02 | ر.س27.00 +17.3% | 3.7% | ر.س28.00 | ر.س26.00 | ر.س34.15 | 2 |
Jan ’24 | ر.س21.90 | ر.س27.00 +23.3% | 3.7% | ر.س28.00 | ر.س26.00 | ر.س38.05 | 2 |
Nov ’23 | ر.س25.80 | ر.س31.00 +20.2% | 9.7% | ر.س34.00 | ر.س28.00 | ر.س29.95 | 2 |
Oct ’23 | ر.س26.15 | ر.س31.00 +18.5% | 9.7% | ر.س34.00 | ر.س28.00 | ر.س35.00 | 2 |
Sep ’23 | ر.س27.75 | ر.س31.00 +11.7% | 9.7% | ر.س34.00 | ر.س28.00 | ر.س37.60 | 2 |
Aug ’23 | ر.س28.95 | ر.س34.50 +19.2% | 18.8% | ر.س41.00 | ر.س28.00 | ر.س39.70 | 2 |
Jul ’23 | ر.س26.00 | ر.س34.50 +32.7% | 18.8% | ر.س41.00 | ر.س28.00 | n/a | 2 |
Jun ’23 | ر.س34.80 | ر.س38.25 +9.9% | 7.2% | ر.س41.00 | ر.س35.50 | ر.س38.75 | 2 |
Analyst Forecast: Target price is less than 20% higher than the current share price.